MIC break points established by the CLSI for ZINFORO®:
In vitro susceptibility testing break points1,2
Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
MIC break points established by the EUCAST for ZINFORO®:
In vitro susceptibility testing break points1,3
ZINFORO® is a fifth-generation cephalosporin with coverage against key pathogens in CAP and cSSTI, including S. aureus and S. pneumoniae.1,4
Clinical efficacy has been demonstrated against the following pathogens in cSSTI1:
In vitro activity does not always correlate with clinical efficacy.
*Efficacy has been demonstrated in CAP clinical studies against the following pathogens that were susceptible to ceftaroline in vitro: S. pneumoniae, S. aureus (methicillin-susceptible strains only), E. coli, H. influenzae, H. parainfluenzae and K. pneumoniae.
Efficacy has been demonstrated in clinical studies of cSSTI against pathogens that were susceptible to ZINFORO® in vitro.1
†The break point for susceptibility is based on a dosage regimen of ceftaroline 600 mg administered q12h.2
‡The available clinical data cannot substantiate efficacy against PNSP. In vitro data indicate that the following atypical species are not susceptible to ZINFORO®: Chlamydophila spp., Legionella spp., Mycoplasma spp., Proteus spp. and P. aeruginosa.1
§Refers to dosing of adults or adolescents (from 12 years of age and weight 33 kg) with ceftaroline q12h using 1-hour infusions.1
IIRefers to dosing of adults or adolescents (from 12 years of age and weight 33 kg) with ceftaroline q8h using 2-hour infusions to treat cSSTI.
S. aureus with ceftaroline MICs ≥4 mg/mL is rare. PK/PD analyses suggest that dosing of adults or adolescents (from 12 years of age and weight 33 kg) with ceftaroline q8h using 2-hour infusions may treat cSSTI due to S. aureus for which ceftaroline MIC is 4 mg/mL.1
¶Inferred by susceptibility to benzylpenicillin.3
CAP, community-acquired pneumonia; CLSI, Clinical and Laboratory Standards Institute; cSSTI, complicated skin and soft tissue infection; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; PD, pharmacodynamic; PNSP, penicillin-non–susceptible strains of S. pneumoniae; PK, pharmacokinetic; q8h, every 8 hours; q12h, every 12 hours.
References:
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.